Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.


Clinical Trial Description

OUTLINE: Patients receive carmustine intravenously (IV) on day -6, etoposide IV and cytarabine IV twice daily (BID) on days -5 to -2, melphalan IV on day -1, and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone orally (PO) once daily (QD) on days 7-21, followed by 2 week taper. After completion of study treatment, patients are followed up at 3 months, 1 year, and then annually thereafter for up to 5 years. ;


Study Design


Related Conditions & MeSH terms

  • Autoimmune Disease
  • Autoimmune Diseases
  • Autoimmune Diseases of the Nervous System
  • Autoimmune Nervous System Disorder
  • Autologous Transplant Autoimmune
  • Central Nervous System Vasculitis
  • Cerebellar Degeneration
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • CIDP Transplant
  • Encephalitis
  • HCT for Neurologic Autoimmune Disorders
  • Lambert Eaton Myasthenic Syndrome
  • Lambert-Eaton Myasthenic Syndrome
  • MS Stem Cell Transplant
  • Multiple Sclerosis
  • Multiple Sclerosis Stem Cell Transplant
  • Multiple Sclerosis Transplant
  • Muscle Weakness
  • Myasthenia Gravis
  • Myasthenia Gravis Transplant
  • Myoclonus
  • Nervous System Diseases
  • Neurologic Autoimmune Disease
  • Neuromyelitis Optica
  • Ocular Motility Disorders
  • Opsoclonus Myoclonus Syndrome
  • Opsoclonus-Myoclonus Syndrome
  • Polyneuropathies
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
  • Rasmussen Subacute Encephalitis
  • Sclerosis
  • Stiff Person Syndrome
  • Stiff-Person Syndrome
  • Syndrome
  • Vasculitis
  • Vasculitis, Central Nervous System

NCT number NCT00716066
Study type Interventional
Source Fred Hutchinson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 2008
Completion date January 31, 2030

See also
  Status Clinical Trial Phase
Completed NCT05039190 - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients Phase 3
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Phase 3
Completed NCT00285350 - Mycophenolate Mofetil in Myasthenia Gravis Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05694234 - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting NCT05095103 - Immune Profiles in Myasthenia Gravis
Not yet recruiting NCT04965987 - Oxaloacetate in Myasthenia Gravis Phase 1
Completed NCT02066519 - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis N/A
Terminated NCT02102594 - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Phase 2
Completed NCT02774239 - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Phase 3
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated NCT01828294 - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Phase 1
Terminated NCT00727194 - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT04590716 - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting NCT04837625 - Study of Myasthenic Crisis in China
Not yet recruiting NCT01469858 - Perception and Multisensory Integration in Neurological Patients Using fMRI N/A
Completed NCT05408702 - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed NCT03205306 - Myasthenia Gravis and Psyche